Efficient transduction and seeding of human endothelial cells onto metallic stents using bicistronic pseudo-typed retroviral vectors encoding vascular endothelial growth factor

Cardiovascular Revascularization Medicine

Volumn 7, Issue 3, 2006, Pages 173-178

  Koren, Belly ^a   Weisz, Anat ^a   Fischer, Lukas ^a   Gluzman, Zoya ^a   Preis, Meir ^a   Avramovitch, Naomi ^a   Cohen, Tzafra ^a   Cosset, Francois Loic ^b   Lewis, Basil S ^a   Flugelman, Moshe Y ^a  

^a CARMEL MEDICAL CENTER   (Israel)

^b CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

Author keywords

Endothelial cells; Pseudo typed retroviral vectors; Stents; VEGF

Indexed keywords

BETA GALACTOSIDASE; METAL; RETROVIRUS VECTOR; VASCULOTROPIN; VASCULOTROPIN C;

ARTICLE; CELL SELECTION; CORONARY STENT; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEASIBILITY STUDY; FLUORESCENCE; GENE TRANSFER; GENETIC CODE; GENETIC ENGINEERING; GIBBON LEUKEMIA VIRUS; HUMAN; HUMAN CELL; MICROSCOPY; PRIORITY JOURNAL; PROTEIN SECRETION; SAPHENOUS VEIN; TIME;

BETA-GALACTOSIDASE; BLOOD VESSEL PROSTHESIS; BLOTTING, WESTERN; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EQUIPMENT DESIGN; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; LAC OPERON; LEUKEMIA VIRUS, GIBBON APE; METALS; SAPHENOUS VEIN; STENTS; TRANSDUCTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33747877120     PISSN: 15538389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carrev.2005.12.007     Document Type: Article

References (21)

1. Van Belle E., Tio F., Couffinhal T., Maillard L., Chen D., Kearney M., and Isner J. Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening. J Am Coll Cardiol 29 (1997) 1371-1379
2. Wilcox J. Thrombin and other potential mechanisms underlying restenosis. Circulation 84 (1991) 432-435
3. Van Belle E., Tio F., Chen D., Maillard L., Passeri J., and Isner J. Stent endothelialization. Time course, impact of local catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition. Circulation 95 (1997) 438-448
4. Dichek D., Neville R., Zwiebel J., Freeman S., Leon M., and Anderson W. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation 80 (1989) 1347-1353
5. Lewis B., Flugelman M., Weisz A., Keren-Tal I., and Schaper W. Angiogenesis by gene therapy: where do we stand?. Cardiovasc Res 35 (1997) 490-497
6. Panetta C., Miyauchi K., Berry D., Simari R., Holmes D., Schwartz R., and Caplice M. A tissue-engineered stent for cell-based vascular gene transfer. Hum Gene Ther 13 (2002) 433-441
7. Klugherz B., Jones P., Cui X., Chen W., Meneveau N., DeFelice S., Connolly J., Wilensky R., and Levy R. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat Biotechnol 18 (2000) 1181-1184
8. Klugherz B., Song C., DeFelice S., Cui X., Lu Z., Connolly J., Hinson J., Wilensky R., and Levy R. Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus. Hum Gene Ther 13 (2002) 443-454
9. Gaspar H., Parsley K., Howe S., King D., Gilmour K., Sinclair J., Brouns G., Schmidt M., Von Kalle C., Barington T., Jakobsen M., Christensen H., Al Ghonaium A., White H., Smith J., Levinsky R., Ali R., Kinnon C., and Thrasher A. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364 9452 (2004) 2181-2187
10. Flugelman M., Virmani R., Leon M., Bowman R., and Dichek D. Genetically engineered endothelial cells remain adherent and viable after stent deployment and exposure to pulsatile flow. Circ Res 70 (1992) 348-354
11. Flugelman M., Rome J., Virmani R., Newman K., and Dichek D. Detection of genetically engineered endothelial cells seeded on endovascular prosthesis ten days after in vivo deployment. J Mol Cell Cardiol 25 Suppl I (1993) S 38
12. Cosset F., Takeuchi Y., Battini J., Weiss R., and Collins M. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 69 (1995) 7430-7436
13. Weisz A., Koren B., Cohen T., Neufeld G., Kleinberger T., Lewis B., and Flugelman M. Increased VEGF165 binding to KDR receptor following infection of human endothelial cells by recombinant adenovirus encoding the Vegf165 gene. Circulation 103 (2001) 1887-1892
14. Marandin A., Dubart A., Pflumio F., Cosset F.-L., Cordette V., Chapel-Fernandes S., Coulombel L., Vainchenker W., and Louache F. Retrovirus-mediated gene transfer into human CD34+ 38 low primitive cells capable of reconstituting long-term cultures in vitro and nonobese diabetic-severe combined immunodeficiency mice in vivo. Hum Gene Ther 9 (1998) 1497-1511
15. Movassagh M., Desmyter C., Baillou C., Chapel-Fernandes S., Guigon M., Klatzmann D., and Lemoine F. High-level gene transfer to cord blood progenitors using gibbon ape leukemia virus pseudotype retroviral vectors and an improved clinically applicable protocol. Hum Gene Ther 9 (1998) 225-234
16. Sanes J., Rubenstein J., and Nicolas J. Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos. EMBO J 5 (1986) 3133-3142
17. Celletti F., Waugh J., Amabile P., Brendolan A., Hilfiker P., and Dake M. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 7 (2001) 425-429
18. Celletti F., Hilfiker P., Ghafouri P., and Dake M. Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. J Am Coll Cardiol 37 (2001) 2126-2130
19. Lemstrom K., Krebs R., Nykanen A., Tikkanen J., Sihvola R., Aaltola E., Hayry P., Wood J., Alitalo K., Yla-Herttuala S., and Koskinen P. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 105 (2002) 2524-2530
20. Isner J., Vale P., Symes J., and Losordo D. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res 89 (2001) 389-400
21. Staudacher D., Preis M., Lewis B., Grossman P., and Flugelman M. Cellular and molecular therapeutic modalities for arterial obstructive syndromes. Pharmacol Ther 109 (2006) 263-273